{"id":"NCT05692154","sponsor":"Opella Healthcare Group SAS, a Sanofi Company","briefTitle":"A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis","officialTitle":"A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-23","primaryCompletion":"2023-03-14","completion":"2023-03-14","firstPosted":"2023-01-20","resultsPosted":"2024-05-16","lastUpdate":"2025-09-09"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Fexofenadine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A (active-active)","type":"EXPERIMENTAL"},{"label":"Arm B (placebo-active)","type":"EXPERIMENTAL"}],"summary":"This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms.\n\nThe total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.","primaryOutcome":{"measure":"Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)","timeFrame":"From 0 hour to 6 hours at Day 4","effectByArm":[{"arm":"Arm A (Active-active)","deltaMin":16.96,"sd":9.09},{"arm":"Arm B (Placebo-active)","deltaMin":21.42,"sd":10.431}],"pValues":[{"comp":"OG000 vs OG001","p":"0.038"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25295&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Headache","Nasal obstruction","Oedema mucosal","Nasal oedema","Tinnitus"]}}